Publications

Search ACTG publications from 1/1/2006 to current.

Search

Filter results by

Found 747 results
Found 747 results.

2018

Taiwo BO, Zheng L, Stefanescu A, et al. "ACTG A5353: A Pilot Study of Dolutegravir Plus Lamivudine for Initial Treatment of Human Immunodeficiency Virus-1 (HIV-1)-infected Participants With HIV-1 RNA <500000 Copies/mL." Clin. Infect. Dis.. 2018;66(11):1689-1697.
Tracy LRA, Struble K, Firnhaber C, et al. "Age Differences by Sex in Antiretroviral-Naïve Participants: Pooled Analysis from Randomized Clinical Trials." J Assoc Nurses AIDS Care. 2018;29(3):371-382.
Presti RM, Handley SA, Droit L, et al. "Alterations in the oral microbiome in HIV-infected participants after antiretroviral therapy administration are influenced by immune status." AIDS. 2018;32(10):1279-1287.
Cespedes MS, Kang M, Kojic EMilunka, et al. "Anogenital human papillomavirus virus DNA and sustained response to the quadrivalent HPV vaccine in women living with HIV-1." Papillomavirus Res. 2018;6:15-21.
Gandhi M, Ofokotun I, Bacchetti P, et al. "Antiretroviral concentrations in hair strongly predict virologic response in a large HIV treatment-naive clinical trial." Clin. Infect. Dis.. 2018.
Hosseinipour MC, Kang M, Krown SE, et al. "As-Needed versus Immediate Etoposide Chemotherapy in Combination with Antiretroviral Therapy for Mild or Moderate AIDS-associated Kaposi Sarcoma in Resource-Limited Settings: A5264/AMC-067 Randomized Clinical Trial." Clin. Infect. Dis.. 2018.
Sattler FR, Chelliah D, Wu X, et al. "Biomarkers Associated with Death After Initiating Treatment for Tuberculosis and HIV in Patients with Very Low CD Cells." Pathog Immun. 2018;3(1):46-62.
Haas DW, Bradford Y, Verma A, et al. "Brain neurotransmitter transporter/receptor genomics and efavirenz central nervous system adverse events." Pharmacogenet. Genomics. 2018;28(7):179-187.
Kelesidis T, Moser CB, Johnston E, et al. "Brief Report: Changes in Plasma RANKL-Osteoprotegerin in a Prospective, Randomized Clinical Trial of Initial Antiviral Therapy: A5260s." J. Acquir. Immune Defic. Syndr.. 2018;78(3):362-366.
Angelidou K, Hunt PW, Landay AL, et al. "Changes in Inflammation but Not in T-Cell Activation Precede Non-AIDS-Defining Events in a Case-Control Study of Patients on Long-term Antiretroviral Therapy." J. Infect. Dis.. 2018;218(2):239-248.
Namazi G, Fajnzylber JM, Aga E, et al. "The Control of HIV After Antiretroviral Medication Pause (CHAMP) Study: Posttreatment Controllers Identified From 14 Clinical Studies." J. Infect. Dis.. 2018;218(12):1954-1963.
Gandhi M, Gandhi RT, Stefanescu A, et al. "Cumulative Antiretroviral Exposure Measured in Hair Is Not Associated With Measures of HIV Persistence or Inflammation Among Individuals on Suppressive ART." J. Infect. Dis.. 2018;218(2):234-238.
Ippolito MM, Jacobson JM, Lederman MM, et al. "Effect of Antiretroviral Therapy on Plasma Concentrations of Chloroquine and Desethyl-chloroquine." Clin. Infect. Dis.. 2018;67(10):1617-1620.
Shivakoti R, Ewald ER, Gupte N, et al. "Effect of baseline micronutrient and inflammation status on CD4 recovery post-cART initiation in the multinational PEARLS trial." Clin Nutr. 2018.
Strongin Z, Sharaf R, D VanBelzen J, et al. "Effect of Short-Term Antiretroviral Therapy Interruption on Levels of Integrated HIV DNA." J. Virol.. 2018;92(12).
Stockdale AJ, Saunders MJ, Boyd MA, et al. "Effectiveness of Protease Inhibitor/Nucleos(t)ide Reverse Transcriptase Inhibitor-Based Second-line Antiretroviral Therapy for the Treatment of Human Immunodeficiency Virus Type 1 Infection in Sub-Saharan Africa: A Systematic Review and Meta-analysis." Clin. Infect. Dis.. 2018;66(12):1846-1857.
MacBrayne CE, Marks KM, Fierer DS, et al. "Effects of sofosbuvir-based hepatitis C treatment on the pharmacokinetics of tenofovir in HIV/HCV-coinfected individuals receiving tenofovir disoproxil fumarate." J. Antimicrob. Chemother.. 2018;73(8):2112-2119.
Li B, Verma SS, Veturi YC, et al. "Evaluation of PrediXcan for prioritizing GWAS associations and predicting gene expression." Pac Symp Biocomput. 2018;23:448-459.
Moro RN, Scott NA, Vernon A, et al. "Exposure to Latent Tuberculosis Treatment during Pregnancy. The PREVENT TB and the iAdhere Trials." Ann Am Thorac Soc. 2018;15(5):570-580.
Kelly SG, Wu K, Tassiopoulos K, Erlandson KM, Koletar SL, Palella FJ. "Frailty is an independent risk factor for mortality, cardiovascular disease, bone disease and diabetes among aging adults with HIV." Clin. Infect. Dis.. 2018.
Figueroa DB, Madeen EP, Tillotson J, et al. "Genetic Variation of the Kinases That Phosphorylate Tenofovir and Emtricitabine in Peripheral Blood Mononuclear Cells." AIDS Res. Hum. Retroviruses. 2018;34(5):421-429.
Gianella S, Marconi VC, Berzins B, et al. "Genital HIV-1 Shedding With Dolutegravir (DTG) Plus Lamivudine (3TC) Dual Therapy." J. Acquir. Immune Defic. Syndr.. 2018;79(5):e112-e114.
Kallianpur AR, Gerschenson M, Hulgan T, et al. "Hemochromatosis (HFE) Gene Variants Are Associated with Increased Mitochondrial DNA Levels During HIV-1 Infection and Antiretroviral Therapy." AIDS Res. Hum. Retroviruses. 2018;34(11):942-949.
Ngongondo MN, Miyahara S, Hughes MD, et al. "Hepatotoxicity During Isoniazid Preventive Therapy and Antiretroviral Therapy in People Living With HIV With Severe Immunosuppression: A Secondary Analysis of a Multi-Country Open-Label Randomized Controlled Clinical Trial." J. Acquir. Immune Defic. Syndr.. 2018;78(1):54-61.
Cranston RD, Cespedes MS, Paczuski P, et al. "High Baseline Anal Human Papillomavirus and Abnormal Anal Cytology in a Phase 3 Trial of the Quadrivalent Human Papillomavirus Vaccine in Human Immunodeficiency Virus-Infected Individuals Older Than 26 Years: ACTG 5298." Sex Transm Dis. 2018;45(4):266-271.
Robertson KR, Jiang H, Kumwenda J, et al. "HIV Associated Neurocognitive Impairment in Diverse Resource Limited Settings." Clin. Infect. Dis.. 2018.

Pages